EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Achievement of Clinically Meaningful Treat-to-Target Thresholds with Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from ONWARD1 and ONWARD2

Benjamin D. Ehst, Joe K. Tung, E. James Song, Todd Schlesinger, Naiem T. Issa, Harrison P. Nguyen, Yuri Klyachkin, Yi Mu, Komal Bawa, April W. Armstrong

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s809

DOI: 10.25251/r0y4wy85 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Benjamin D. Ehst und 9 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Envudeucitinib (ESK-001), an investigational highly selective oral next-generation allosteric TYK2 inhibitor, was evaluated in patients with moderate-to-severe plaque psoriasis in the replicate Phase 3 ONWARD1 and ONWARD2 trials.1 This post-hoc analysis evaluated the achievement of clinically relevant treat-to-target thresholds2,3 for Psoriasis Area and Severity Index (PASI) and body surface area (BSA) in both studies.

Methods

ONWARD1 and ONWARD2 randomized patients to envudeucitinib 40 mg BID (n=459/433), placebo (n=230/211, crossing over to envudeucitinib after Week 16), or apremilast 30 mg BID (n=223/215). Absolute PASI thresholds (0, ≤1, and ≤2,) and BSA (≤3%, ≤1%) were calculated post-hoc and assessed at Week 16 (vs placebo and apremilast) and Week 24 (vs apremilast) using non-responder imputation. Mean percent change from baseline in PASI was also summarized descriptively at Weeks 16 and 24 using modified baseline observation carried forward (mBOCF) imputation.

Results

At Week 16, significantly more patients treated with envudeucitinib achieved clinically meaningful absolute PASI treatment targets than those receiving placebo or apremilast across both ONWARD1 and ONWARD2. At Week 16, absolute PASI thresholds with envudeucitinib vs placebo in ONWARD1 and ONWARD2 were, respectively: PASI=0, 29.4% vs 0.9% and 27.7% vs 0.9%; ≤1, 44.7% vs 3% and 40.9% vs 1.4%; and ≤2, 61.7% vs 7.4% and 55.9% vs 4.7%; (all p

Zitieren

APA

Ehst, B. D., Tung, J. K., Song, E. J., Schlesinger, T., Issa, N. T., Nguyen, H. P., Klyachkin, Y., Mu, Y., Bawa, K., & Armstrong, A. W. (2026). Achievement of Clinically Meaningful Treat-to-Target Thresholds with Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from ONWARD1 and ONWARD2. SKIN The Journal of Cutaneous Medicine, 10(6), s809. https://doi.org/10.25251/r0y4wy85

Vancouver

Ehst BD, Tung JK, Song EJ, Schlesinger T, Issa NT, Nguyen HP, et al. Achievement of Clinically Meaningful Treat-to-Target Thresholds with Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from ONWARD1 and ONWARD2. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s809. doi:10.25251/r0y4wy85

BibTeX
@article{Ehst2026,
  author = {Ehst, Benjamin D. and Tung, Joe K. and Song, E. James and Schlesinger, Todd and Issa, Naiem T. and Nguyen, Harrison P. and Klyachkin, Yuri and Mu, Yi and Bawa, Komal and Armstrong, April W.},
  title = {Achievement of Clinically Meaningful Treat-to-Target Thresholds with Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from ONWARD1 and ONWARD2},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s809},
  doi = {10.25251/r0y4wy85}
}
Kostenlos starten →